Literature DB >> 16518061

Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer.

Katsumasa Kuroi1, Masakazu Toi, Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama.   

Abstract

BACKGROUND: Emerging evidence suggests that induction of pathologic complete response (pCR) after primary systemic therapy (PST) is, at least to some extent, predictive of survival. However, standards for processing surgical specimens and for histopathologic evaluation of the pathologic response to therapy appear to be lacking.
METHODS: To perform a systematic review of representative articles on this topic, a computerized (MEDLINE) search was undertaken followed by a manual search based on the reference lists of the publications identified.
RESULTS: Several classification systems have been used to assess pathologic response to PST, the term pCR has not been applied in a consistent standardized manner, and only limited information is available about the reliability and validity of these classification systems. However, definitions of pCR can be summarized as follows: near pCR, only focal invasive tumor residues in the removed breast; quasi pCR, total or near total disappearance of invasive tumor in the removed breast; pCRinv, only in situ tumor residual in the removed breast; comprehensive pCR, no evidence of residual invasive tumor in the removed breast; strict pCR, disappearance of all tumor cells in the removed breast; comprehensive pCR (br+n), no evidence of residual invasive tumor in the breast and axillary nodes; strict pCR (br+n), no malignant tumor cells in the removed breast and axillary nodes. Comparison of the use of the term "pCR" in various trials reveals that it is not applied equivalently in these studies.
CONCLUSION: Assessment of pCR needs to be standardized, with verification for reliability and validity. For now, the non-equivalency in the definition of pCR should be taken into account when comparing the results of PST.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518061     DOI: 10.2325/jbcs.13.38

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  11 in total

1.  The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.

Authors:  Takashi Ishikawa; Takeshi Sasaki; Mikiko Tanabe; Kazutaka Narui; Kumiko Kida; Kazuhiro Shimada; Daisuke Shimizu; Akimitsu Yamada; Satoshi Morita; Mari S Oba; Kae Kawachi; Akinori Nozawa; Yasushi Ichikawa; Kazuaki Takabe; Itaru Endo
Journal:  J Surg Sci       Date:  2014-12

2.  Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Authors:  A J Montero; C M Diaz-Montero; Y E Deutsch; J Hurley; L G Koniaris; T Rumboldt; S Yasir; M Jorda; E Garret-Mayer; E Avisar; J Slingerland; O Silva; C Welsh; K Schuhwerk; P Seo; M D Pegram; S Glück
Journal:  Breast Cancer Res Treat       Date:  2011-12-03       Impact factor: 4.872

3.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Authors:  Elena Provenzano; Veerle Bossuyt; Giuseppe Viale; David Cameron; Sunil Badve; Carsten Denkert; Gaëtan MacGrogan; Frédérique Penault-Llorca; Judy Boughey; Giuseppe Curigliano; J Michael Dixon; Laura Esserman; Gerd Fastner; Thorsten Kuehn; Florentia Peintinger; Gunter von Minckwitz; Julia White; Wei Yang; W Fraser Symmans
Journal:  Mod Pathol       Date:  2015-07-24       Impact factor: 7.842

4.  Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy.

Authors:  Mitsuhiro Hayashi; Kazuharu Kai; Yasuhiro Okumura; Tomofumi Osako; Nobuyuki Arima; Hirotaka Iwase; Reiki Nishimura
Journal:  Oncol Lett       Date:  2011-01-11       Impact factor: 2.967

5.  Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection.

Authors:  Thalia Erbes; Marzenna Orlowska-Volk; Axel Zur Hausen; Gerta Rücker; Sebastian Mayer; Matthias Voigt; Juliane Farthmann; Severine Iborra; Marc Hirschfeld; Philipp T Meyer; Gerald Gitsch; Elmar Stickeler
Journal:  BMC Cancer       Date:  2014-01-03       Impact factor: 4.430

6.  The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.

Authors:  Ivett Teleki; Tibor Krenacs; Marcell A Szasz; Janina Kulka; Barna Wichmann; Cornelia Leo; Barbel Papassotiropoulos; Cosima Riemenschnitter; Holger Moch; Zsuzsanna Varga
Journal:  BMC Cancer       Date:  2013-02-02       Impact factor: 4.430

7.  XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer.

Authors:  Stefan Glück; Edward F McKenna; Melanie Royce
Journal:  Int J Med Sci       Date:  2008-11-04       Impact factor: 3.738

8.  Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Authors:  Maike Sonnenberg; Heiko van der Kuip; Silke Haubeis; Peter Fritz; Werner Schroth; Godehard Friedel; Wolfgang Simon; Thomas E Mürdter; Walter E Aulitzky
Journal:  BMC Cancer       Date:  2008-12-11       Impact factor: 4.430

Review 9.  An overview of the Japan Breast Cancer Research Group (JBCRG) activities.

Authors:  Shinji Ohno; Katsumasa Kuroi; Masakazu Toi
Journal:  Breast Cancer       Date:  2013-03-15       Impact factor: 4.239

10.  Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.

Authors:  Katsumasa Kuroi; Masakazu Toi; Shinji Ohno; Seigo Nakamura; Hiroji Iwata; Norikazu Masuda; Nobuaki Sato; Hitoshi Tsuda; Masafumi Kurosumi; Futoshi Akiyama
Journal:  Breast Cancer       Date:  2014-02-27       Impact factor: 4.239

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.